Inari Medical, Inc. (NASDAQ:NARI) Shares Sold by Fiera Capital Corp

Fiera Capital Corp reduced its position in Inari Medical, Inc. (NASDAQ:NARI - Free Report) by 6.3% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 527,990 shares of the company's stock after selling 35,577 shares during the quarter. Fiera Capital Corp owned about 0.90% of Inari Medical worth $26,954,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of NARI. Jennison Associates LLC lifted its holdings in shares of Inari Medical by 11.8% during the fourth quarter. Jennison Associates LLC now owns 1,763,258 shares of the company's stock worth $90,014,000 after purchasing an additional 186,617 shares during the period. Vestal Point Capital LP raised its position in Inari Medical by 342.9% in the third quarter. Vestal Point Capital LP now owns 1,550,000 shares of the company's stock worth $63,922,000 after acquiring an additional 1,200,000 shares in the last quarter. Bamco Inc. NY raised its position in Inari Medical by 29.5% in the third quarter. Bamco Inc. NY now owns 1,006,129 shares of the company's stock worth $41,493,000 after acquiring an additional 228,977 shares in the last quarter. The Manufacturers Life Insurance Company raised its position in Inari Medical by 101.3% in the third quarter. The Manufacturers Life Insurance Company now owns 795,099 shares of the company's stock worth $32,790,000 after acquiring an additional 400,198 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. raised its position in Inari Medical by 0.4% in the third quarter. Charles Schwab Investment Management Inc. now owns 453,972 shares of the company's stock worth $18,722,000 after acquiring an additional 1,783 shares in the last quarter. 90.98% of the stock is owned by institutional investors and hedge funds.

Inari Medical Price Performance

Inari Medical stock remained flat at $79.93 during midday trading on Friday. The company had a trading volume of 1,012,995 shares, compared to its average volume of 2,432,933. The firm has a market capitalization of $4.68 billion, a P/E ratio of -59.21 and a beta of 1.02. The company's 50-day moving average is $69.07 and its 200-day moving average is $54.31. Inari Medical, Inc. has a 1 year low of $36.73 and a 1 year high of $79.97.

Insider Buying and Selling

In related news, Director William Hoffman sold 200,000 shares of Inari Medical stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $60.47, for a total transaction of $12,094,000.00. Following the completion of the sale, the director now owns 238,987 shares in the company, valued at approximately $14,451,543.89. This trade represents a 45.56 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Andrew Hykes sold 3,000 shares of Inari Medical stock in a transaction dated Friday, December 20th. The stock was sold at an average price of $55.29, for a total value of $165,870.00. Following the sale, the chief executive officer now owns 439,310 shares of the company's stock, valued at approximately $24,289,449.90. This represents a 0.68 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 323,000 shares of company stock worth $18,669,070. 10.60% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several research analysts have issued reports on the company. Baird R W cut Inari Medical from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, January 7th. William Blair reiterated a "market perform" rating on shares of Inari Medical in a research report on Tuesday, January 7th. Canaccord Genuity Group reiterated a "hold" rating and issued a $80.00 price objective (up previously from $74.00) on shares of Inari Medical in a research report on Tuesday, January 7th. Robert W. Baird restated a "neutral" rating and issued a $80.00 price target (down previously from $81.00) on shares of Inari Medical in a research report on Tuesday, January 7th. Finally, Truist Financial raised their price target on Inari Medical from $50.00 to $63.00 and gave the company a "hold" rating in a research report on Wednesday, December 18th. Twelve investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Hold" and an average target price of $68.00.

Inari Medical Company Profile

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.